RetractedArticleOncogene2022
Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
Boya Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this papercites it
RetractedArticleOncogene2022
Boya Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.